CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study

Leukemia & lymphoma, Nov 2021 | 1-5

DOI: 10.1080/10428194.2021.1986219

CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study

Duell, Johannes ; Obr, Aleš ; Augustin, Marinela ; Endell, Jan ; Liu, Hao ; Geiger, Sabine ; Silverman, Ian M ; Ambarkhane, Sumeet ; Rosenwald, Andreas

PRODUCTS USED

NGS

Read Full Article

ABSTRACT

Read Full Article

PRODUCTS USED

NGS

Genes

Oligo Pools

NGS Target Enrichment Solutions

Variant Libraries

Synthetic Controls

Antibody Discovery

CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study

PRODUCTS USED

ABSTRACT

PRODUCTS USED

Related Publications

Systemic evaluation of genetic variants in transcriptomic changes of systemic immune landscapes in non-small cell lung cancer patients treated with immune checkpoint inhibitors

Bright mutant beetle luciferases: performance in bioluminescence detection in live mammalian cells and insights into their spectral mechanism by tagging them with fluorescent proteins

Bacteria sense virus-induced genome degradation via methylated mononucleotides